Therapeutic management of DRESS: A retrospective study of 38 cases

Journal of the American Academy of Dermatology

Volumn 72, Issue 2, 2015, Pages 246-252

  Funck Brentano, Elisa ^a,c   Duong, Tu Anh ^a   Bouvresse, Sophie ^a   Bagot, Martine ^b   Wolkenstein, Pierre ^a   Roujeau, Jean Claude ^a   Chosidow, Olivier ^a   Valeyrie Allanore, Laurence ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Drug reaction with eosinophilia and systemic symptoms; Drug induced hypersensitivity syndrome; Severe cutaneous adverse reactions; Systemic corticosteroids treatment; Therapeutic management; Topical steroids

Indexed keywords

ALLOPURINOL; AMIODARONE; AMOXICILLIN; CARBAMAZEPINE; COTRIMOXAZOLE; DAPSONE; FLUINDIONE; LAMOTRIGINE; MINOCYCLINE; NADROPARIN; OMEPRAZOLE; PANTOPRAZOLE; PHENOBARBITAL; PHENYTOIN; PIPERACILLIN PLUS TAZOBACTAM; SALAZOSULFAPYRIDINE; STEROID; TERBINAFINE; TIAPRIDE; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; DEMOGRAPHY; DRESS SYNDROME; EOSINOPHILIA; FACE EDEMA; FEMALE; FISHER EXACT TEST; HUMAN; LIVER FAILURE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NERVOUS SYSTEM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; DRUG HYPERSENSITIVITY SYNDROME; TOPICAL DRUG ADMINISTRATION; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG HYPERSENSITIVITY SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEROIDS; YOUNG ADULT;

EID: 84922567626     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.10.032     Document Type: Article

References (34)

1. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg. 1996;15:250-257.
2. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med. 1995;155:2285-2290.
3. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology. 1997;49:542-546.
4. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209:123-129.
5. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol. 2007;156:1083-1084.
6. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156:609-611.
7. Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071-1080.
8. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.
9. Chen YC, Chang CY, Cho YT, Chiu HC, Chu CY. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol. 2013;68:459-465.
10. Yun SJ, Lee JB, Kim EJ, et al. Drug rash with eosinophilia and systemic symptoms induced by valproate and carbamazepine: formation of circulating auto-antibody against 190-kDa antigen. Acta Derm Venereol. 2006;86:241-244.
11. Colvin JH, Sheth AP. Minocycline hypersensitivity syndrome with hypotension mimicking septic shock. Pediatr Dermatol. 2001;18:295-298.
12. Abe M, Furukawa S, Takayama S, et al. Drug-induced hepatitis with autoimmune features during minocycline therapy. Intern Med. 2003;42:48-52.
13. Chiou CC, Yang LC, Hung SI, et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol. 2008;22:1044-1049.
14. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome, part II: management and therapeutics. J Am Acad Dermatol. 2013;68: 709.e1-709.e9; quiz 18-20.
15. Ushigome Y, Kano Y, Ishida T, Hirahara K, Shiohara T. Shortand long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol. 2013;68:721-728.
16. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J. 2002;8:5.
17. Descamps V, Ben Said B, Sassolas B, et al. Management of drug reaction with eosinophilia and systemic symptoms (DRESS) [in French]. Ann Dermatol Venereol. 2010;137: 703-708.
18. Natkunarajah J, Goolamali S, Craythorne E, et al. Ten cases of drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone. Eur J Dermatol. 2011;21:385-391.
19. Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology. 2003;206:353-356.
20. Nagai Y, Hattori T, Ishikawa O. A case of hypersensitivity syndrome due to phenytoin. J Dermatol. 2002;29:670-673.
21. Um SJ, Lee SK, Kim YH, et al. Clinical features of drug-induced hypersensitivity syndrome in 38 patients. J Investig Allergol Clin Immunol. 2010;20:556-562.
22. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346:321-327.
23. Correia O, Delgado L, Roujeau JC, Le Cleach L, Fleming-Torrinha JA. Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch Dermatol. 2002;138: 29-32.
24. Kano Y, Inaoka M, Sakuma K, Shiohara T. Virus reactivation and intravenous immunoglobulin (IVIG) therapy of druginduced hypersensitivity syndrome. Toxicology. 2005;209: 165-167.
25. Choquet-Kastylevsky G, Intrator L, Chenal C, Bocquet H, Revuz J, Roujeau JC. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol. 1998;139:1026-1032.
26. Mardivirin L, Valeyrie-Allanore L, Branlant-Redon E, et al. Amoxicillin-induced flare in patients with DRESS (drug reaction with eosinophilia and systemic symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on human herpesvirus 6 replication in vitro. Eur J Dermatol. 2010;20:68-73.
27. Kuntz-Simon G, Obert G. Sodium valproate, an anticonvulsant drug, stimulates human cytomegalovirus replication. J Gen Virol. 1995;76:1409-1415.
28. Ben m'rad M, Leclerc-Mercier S, Blanche P, et al. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore). 2009;88: 131-140.
29. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136:323-327.
30. Descamps V, Collot S, Mahe E, Houhou N, Crickx B, Ranger-Rogez S. Active human herpesvirus 6 infection in a patient with drug rash with eosinophilia and systemic symptoms. J Invest Dermatol. 2003;121:215-216.
31. Joly P, Janela B, Tetart F, et al. Poor benefit/risk balance of intravenous immunoglobulins in DRESS. Arch Dermatol. 2012; 148:543-544.
32. Kito Y, Ito T, Hashizume H, Tokura Y. High-dose intravenous immunoglobulin monotherapy for drug-induced hypersensitivity syndrome. Acta Derm Venereol. 2012;92:100-101.
33. Comfere NI, Sartori-Valinotti JC, Bruce AJ, Drage LA. Successful treatment of lamotrigine-associated drug hypersensitivity syndrome with intravenous IgG. J Am Acad Dermatol. 2012; 66:e249-e250.
34. Singer EM, Wanat KA, Rosenbach MA. A case of recalcitrant DRESS syndrome with multiple autoimmune sequelae treated with intravenous immunoglobulins. JAMA Dermatol. 2013;149: 494-495.